	US 12,275,955 B2
	Combining iPSC derived effector cell types for immunotherapy use
Bahram Valamehr, San Diego, CA (US); Jode Goodridge, San Diego, CA (US); and Ryan Bjordahl, San Diego, CA (US)
Assigned to FATE THERAPEUTICS, INC., San Diego, CA (US)
Appl. No. 18/002,248
Filed by Fate Therapeutics, Inc., San Diego, CA (US)
PCT Filed Jun. 18, 2021, PCT No. PCT/US2021/038134 § 371(c)(1), (2) Date Dec. 16, 2022, PCT Pub. No. WO2021/258016, PCT Pub. Date Dec. 23, 2021.
Claims priority of provisional application 63/041,672, filed on Jun. 19, 2020.
Prior Publication US 2023/0235287 A1, Jul. 27, 2023
Int. Cl. C12N 5/0783 (2010.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/715 (2006.01); C07K 14/735 (2006.01)

CPC C12N 5/0636 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4613 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61P 35/00 (2018.01); C07K 14/70535 (2013.01); C07K 14/7155 (2013.01); C12N 5/0646 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 2506/45 (2013.01)]

40 Claims

1. A composition comprising two or more synthetic cell populations, wherein the composition comprises:

(i) a first synthetic cell population comprising iPSC-derived NK cells, wherein the iPSC-derived NK cells comprise:

(a) an exogenous CD16; and

(b) a first chimeric antigen receptor (CAR); and

(ii) a second synthetic cell population comprising iPSC-derived T cells, wherein the iPSC-derived T cells comprise: at least a second chimeric antigen receptor (CAR), and wherein the second CAR is expressed under control of an endogenous promoter of a TCR locus.